Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Hope in a pill? ebola drug favipiravir tested in guinea

NCT ID NCT02329054

Disease control Sponsor: Institut National de la Santé Et de la Recherche Médicale, France Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed Phase 2 trial tested the antiviral drug favipiravir in 126 people with Ebola in Guinea. The goal was to see if it could reduce deaths. Participants received high doses of the drug by mouth for up to 10 days. The study aimed to find a practical treatment for Ebola, which currently has no specific cure.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
favipiravir (an antiviral drug)
What this could lead to
If successful, this could provide a simple oral treatment to lower death rates from Ebola, especially in outbreak settings.
What could go wrong
This is a small Phase 2 trial with 126 people, so results may not be definitive. The drug may not work as well in humans as in lab studies, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

126 people

The number who actually took part.

Start date

Dec 2014

Finished

Sep 2015

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

1 year and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * age \>1 year and weighting ≥10kg, * EVD confirmed by a positive qualitative PCR test, * signed informed consent (signed by the parents/adults guardians in case of minor patient). Non inclusion-criteria: * pregnancy\*, * inability to take the drug (encephalopathy, severe vomiting). \* Emergency use of favipiravir in pregnant women outside of the trial is envisaged and under evaluation. In this protocol, the investigators will refer to the following groups according to age and duration of symptoms\*\*: * Group A1: adults with time between first symptoms and first dose of favipiravir ≤72h; * Group A2: adults with time between first symptoms and first dose of favipiravir \>72h; * Group C: all children \>1 year and weighting ≥10kg. Time of first symptom refers to the time of the beginning of any symptom considered to be related to EVD. \*\*Symptoms to be considered will be: acute onset of fever, severe headache, myalgia, extreme fatigue, vomiting, diarrhoea, abdominal pain, or unexplained hemorrhage. The division in groups is a matter of analysis, and will not be perceptible by the patients during the trial process. Patients in the three groups will receive the same treatment and will be followed under the same procedures, with only two exceptions: the number of additional blood sample collections will be lower in group A2 and C (n=2) than in group A1 (n=3) and daily dosages will be adapted to the body weight in group C.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Ebola virus disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Ebola hemorrhagic fever

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Ebola virus disease

Contacts and locations

Locations

  • ALIMA Ebola care center

    Nzérékoré, Guinea

  • French Red Cross Ebola care center

    Macenta, Guinea

  • MSF Ebola treatment centre

    Gueckedou, Guinea

  • The caregivers treatment center

    Conakry, Guinea

More trials for these conditions

Other studies related to the condition(s) this trial covers.